摘要
目的观察并分析瑞替普酶（r PA）联合还原型谷胱甘肽（GSH）对急性ST段抬高型心肌梗死疗效及安全性。方法随机选择2013年4月~2014年4月本院诊治的急性ST段抬高型心肌梗死患者86例,按照不同治疗方式分为两组,对照组43例患者予以单项瑞替普酶治疗,研究组43例患者予以瑞替普酶与还原型谷胱甘肽联合治疗,观察并比较两组患者血管再通率、疗效性指标改善情况及不良事件发生率。结果研究组溶栓后不同时间段（2、4、6 h）血管再通率与对照组比较差异无统计学意义（p〉0.05）;两组治疗后疗效性指标均发生明显改善,其中研究组改善更为显著,且优于对照组治疗后,比较差异均具统计学意义（p〈0.05,p〈0.01）;研究组不良事件发生率显著低于对照组,比较差异具统计学意义（p〈0.05）。结论瑞替普酶联合还原型谷胱治疗STEMI临床疗效显著,可积极改善心功能,且安全性较高。
Objective To observe and analyze the curative effects and safety of reteplase（ r PA） combined with reduced glutathione（ GSH） in the treatment of acute ST segment elevation myocardial infarction. Methods 86 cases of patients with acute ST elevation myocardial infarction in our hospital from April 2013 to April 2014 were randomly selected,and divided equally into two groups according to different treatment methods. 43 patients in the control group were merely given reteplase for treatment,whereas the other 43 in the experiment group were given combined therapy of reteplase and reduced glutathione. The vascular recanalization rate,improvement of effective indicators and incidence of adverse events of patients were compared between the two groups. Results After thrombolysis,the vascular recanalization rate of the experiment group in different time points（ 2 h,4 h and 6 h after thrombolysis）showed no significant difference compared with that of the control group（ p 〉 0. 05）. After the treatment,the effective indicators of the two groups both significantly improved,and the experiment group improved more significantly than the control group（ p 〈 0. 05,p 〈 0. 01）. The incidence of adverse events of the experiment group was significantly lower than that of the control group（ p 〈 0. 05）. Conclusion Reteplase combined with reduced glutathione is of significant curative effect in the treatment of STEMI,which can effectively improve the cardiac function. It is of higher security but with lower incidence of adverse events.
出处
《现代医院》
2015年第5期47-49,共3页
Modern Hospitals
